helping you discover faster
You don’t have time to read everything.
We crystallize the science to help you discover faster.
INDIVIDUAL
discover faster
$99.99
a month when billed annually
$119.99 billed monthly / cancel anytime
Don’t miss key developments because you’re too busy. Upgrade today to:
- Understand why new molecules matter
- Discover ideas for better molecules
- Learn how the best are tackling problems
- Keep track of new tools and technologies
- Stay up-to-date on relevant news
- Save days, if not weeks each month
TEAM
discover together
$85/user
a month when billed annually
$99.99 billed monthly / cancel anytime
Contact us directly to get custom group rates for departments, sites, or institutions.
- Keep everyone up-to-date on best practices
- Make team decisions simpler
- Simple access for each team member
- Painless user management with team account
- Responsive customer support for company invoices
- Guaranteed time-savings
join Premium subscribers at:
AbbVie, GSK, Merck, Sanofi, Boehringer Ingelheim, Novartis, Otsuka, Sarepta, Vividion, ORIC, ARCH Venture Partners, Third Rock Ventures, RA Capital, Google Ventures (GV), Medicxi, 8VC, and many more who are saving “days, if not weeks” of reading each month
access Molecules of the Month deep dives
access new drug approval deep dives

access industry reviews
searchable individual deep dives

and more…
Frequently Asked Questions
Premium Molecules of the Month slide decks are found linked on every Molecules of the Month page and unlocked when logged in. Recent individual molecule pages also have in-depth information that is site-searchable. Recent premium-only articles and slide decks can be found on the Premium page in the navigation menu.
Yes, a receipt is provided with each membership subscription, and custom invoices for company reimbursement can be obtained downloaded directly from the account page online or by contacting billing@drughunter.com.
Companies, research sites, or departments can purchase access for groups of 5+ users at discounted rates either through coupons for individuals paid by the institution, or through a corporate account which can easily grant access to subaccounts by company e-mail address.
A large pharma head of research told us her subscription saves her days, if not weeks of time each month. Consider also the value of getting to a candidate faster with an empowered team, and the cost of a single compound or assay that could be avoided with more context.
Between time savings and the value of enriched ideas, it’s more expensive not to have a subscription!
We’re happy to help set up a demo for your team – just contact us at info@drughunter.com
No, all payments are handled by industry-leading third parties such as Stripe or Plaid. We do not store or handle your sensitive information. See Stripe’s documentation for more information: (https://stripe.com/docs/security/stripe)
Yes, please reach out to info@drughunter.com to get a tailored solution for your organization.
We can work directly with your academic library to set up institutional access. If your library will not cover a subscription, contact us at info@drughunter.com and we may be able to offer a student rate to verified students.
Companies can pay by credit or debit card, ACH transfer, wire transfer, or check for annual subscriptions. We’ll work directly with your accounting team to get your team set up!
You can cancel your monthly subscription at any time online using the membership portal, and cancellations will reflect in the next billing cycle. Annual plans that are cancelled will also not renew on the next billing cycle.
not sure? get free content by email
Not sure?
Already a Member?
RECENT ARTICLES
- Small Molecule and Biotechnology-Based Therapeutics for Neurology-Focused Companies: 2021’s IPOs Part V
- Agile Drug Hunting
- Lenacapavir Synthesis Highlights
- June 2022 Molecules of the Month Runners-Up
- Molecules of the Month – June 2022
- Beginning with the End in Mind: Five Minutes with a Commercial Leader
DRUG DISCOVERY RESOURCES
- Drug Discovery Resources
- Drug Discovery Posters and Cheat Sheets
- Drug Discovery IPOs and Industry Reviews
- Lists of Approved Drugs
- Classics in Drug Discovery
- Drug Discovery Books
- Drug Discovery Conferences
- What is a Drug Hunter?
- Topliss Tree and Topliss Scheme Posters
- PK Reference Table / Cheat Sheet
- Pd-Couplings Table / Cheat Sheet
- Phase I Drug Metabolism
- Approved Covalent Drug Mechanisms
- Why LogD Matters / LogD Poster
- Types of Kinase Inhibitors
- Unusual Molecular Interactions from the PDB
- Bioactivation of Structural Alerts
- The Square Cube Law
- Don’t Work on Things That Don’t Work
- What is a Biologic Drug Anyway?
- Managing Liver Injury (DILI) Risk
- Where Do Hits Come From?
JOIN SUBSCRIBERS from
- Johnson & Johnson
- Roche
- Pfizer
- Novartis
- Bayer
- Merck
- Sanofi
- GlaxoSmithKline
- AbbVie
- Eli Lilly
- Boehringer Ingelheim
- Amgen
- Bristol-Myers Squibb
- Gilead
- AstraZeneca
- Teva
- Novo Nordisk
- Merck KGaA
- Takeda
- Celgene (BMS)
- Biogen
- Astellas
- Daiichi Sankyo
- Regeneron
- UCB
- Eisai
- Servier
- Kyowa Kirin
- Shionogi
- Vertex
- Lundbeck
- Taisho
- Ono
- Seagen
- Incyte
- LEO Pharma
- Janssen
- Galapagos
- Idorsia
- Astex
- Arvinas
- Kymera
- Relay
- Schrodinger
- Mirati
- Revolution
- Nimbus
- Plexxikon
- Forma
- Arcus
- RA Capital
- ARCH Venture Partners
- MPM Capital
- Orbimed
- The Column Group
- 5AM Ventures
- Versant Ventures
- Deerfield
- Goldman Sachs
- Citi
- Piper Sandler
- Softbank
- …and hundreds of others